Pancras C.W. Hogendoorn

Research interests

Publications

• Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

  European Journal of Cancer · 2019 · 10.1016/j.ejca.2018.11.027

• Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30214-5

• Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2014.60.0734

• EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

  Annals of Oncology · 2014 · 10.1093/annonc/mdu526

• The Clinical Approach Toward Giant Cell Tumor of Bone

  The Oncologist · 2014 · 10.1634/theoncologist.2013-0432

• Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70063-4

• WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, vol. 5

  · 2013

• Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70346-7

• Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-10-2047

• IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

  The Journal of Pathology · 2011 · https://doi.org/10.1002/path.2913

• Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

  European Journal of Cancer · 2011 · 10.1016/j.ejca.2011.05.030

• Identification of a novel, recurrent HEY1‐NCOA2 fusion in mesenchymal chondrosarcoma based on a genome‐wide screen of exon‐level expression data

  Genes Chromosomes and Cancer · 2011 · 10.1002/gcc.20937

• Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2010 · 10.1093/annonc/mdq223

• Cartilage tumours and bone development: molecular pathology and possible therapeutic targets

  Nature reviews. Cancer · 2010 · 10.1038/nrc2869

• Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2010 · 10.1093/annonc/mdq223

• Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2

  The Journal of Pathology · 2009 · 10.1002/path.2603

• Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

  Cancer Research · 2009 · https://doi.org/10.1158/0008-5472.can-08-3845

• The Clinical Approach Towards Chondrosarcoma

  The Oncologist · 2008 · https://doi.org/10.1634/theoncologist.2007-0237

• Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup

  JNCI Journal of the National Cancer Institute · 2007 · 10.1093/jnci/djk015

• Sarcoma Derived from Cultured Mesenchymal Stem Cells

  Stem Cells · 2006 · 10.1634/stemcells.2005-0620

• Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

  Annals of Oncology · 2005 · https://doi.org/10.1093/annonc/mdi127

• Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study

  European Journal of Cancer · 2005 · 10.1016/j.ejca.2005.09.009

• Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.11.601

• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

  The Lancet · 2004 · https://doi.org/10.1016/s0140-6736(04)17098-0

• Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

  European Journal of Cancer · 2003 · 10.1016/s0959-8049(02)00836-5

Current projects

No projects listed.